Causeway Bio.
Turning early drug discovery into investable, executable reality
A bridge from early discovery science to venture creation and beyond…
Causeway Bio works at the intersection of:
Early-stage drug discovery
Venture building
Strategic execution
Founded by Tom Coulter, PhD, with 30 years experience across pharma, biotech, CROs, biotech strategy, and early asset development.
I help biotech companies and investors bridge the gap between promising science and high-quality drug discovery execution: across strategy, outsourcing, and value creation.
Contact Us
tom@causeway.bio
(0044) 7990 505653
Areas of Practice
Investor & Transaction Support
Venture Build & Portfolio Support
What I Do
From idea to asset… done properly
Early-stage drug discovery fails less from lack of science, and more from poor translation into executable plans.
I work with biotech companies, venture investors, and venture builders to:
Shape early assets into credible development strategies
Design and manage outsourced drug discovery programmes
Strengthen the link between scientific decisions and commercial value
The focus is simple:
Make early programmes investable, partnerable, and executable.
Early Asset Strategy
Define what you really have… and what it needs to become.
Target and modality positioning
Development strategy (preclinical to IND)
Risk identification and mitigation
Drug Discovery Execution & Outsourcing
Turn plans into high-quality delivery.
CRO selection and management
Programme design and oversight
Translating strategy into day-to-day execution.
See assets the way investors and partners do.
Scientific due diligence
Pipeline and asset evaluation
Framing assets for investment or partnering
Facilitate connection to potential partners
Provide fractional BD support
Support company creation and early growth.
Building discovery plans from scratch
Interim leadership / advisory roles
Working with venture studios and VC portfolios
“Vision without execution is hallucination…”
– Thomas Edison
Get in Touch
tom@causeway.bio